Sold by: OM1
Deployed on AWS
This product provides switching patterns between different biologic disease-modifying antirheumatic drugs (bDMARDs) during first, second, and third lines of bDMARD therapy. All patients in this dataset received treatment with adalimumab (Humira), the best-selling drug in the United States since 2012. Additional datasets and summaries - including focus on other drugs, additional lines of therapy, and specific time periods - are available upon request.
Overview
This product provides switching patterns between different biologic disease-modifying antirheumatic drugs (bDMARDs) during first, second, and third lines of bDMARD therapy. All patients in this dataset received treatment with adalimumab (Humira), the best-selling drug in the United States since 2012. Additional datasets and summaries - including focus on other drugs, additional lines of therapy, and specific time periods - are available upon request. For more information, visit < www.om1.com > and get in touch at info@om1.com .
Details
New
Introducing multi-product solutions
You can now purchase comprehensive solutions tailored to use cases and industries.
Features and programs
Financing for AWS Marketplace purchases
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
Pricing
Pricing is based on the duration and terms of your contract with the vendor. This entitles you to a specified quantity of use for the contract duration. If you choose not to renew or replace your contract before it ends, access to these entitlements will expire.
Additional AWS infrastructure costs may apply. Use the AWS Pricing Calculator to estimate your infrastructure costs.
Dimension | Cost/12 months |
|---|---|
ProductAccess | $999.00 |
Dimensions summary
This listing uses a single contract-based pricing dimension. You buy access under a negotiated agreement rather than by usage, hourly rates, or fixed tiers. The dimension gives you access to the Rheumatoid Arthritis drug switching patterns dataset, which draws on curated real-world clinical data. Because pricing is set by contract, the quantity and term are arranged directly with the vendor. There are no separate tiers, instance sizes, or usage add-ons to compare. You agree on scope and price before access begins.
Top-of-mind questions for buyers
One contract unit covers access to the curated Rheumatoid Arthritis drug switching patterns dataset. This draws on real-world clinical data linked across electronic medical records, claims, labs, and clinical notes. The exact scope, population, and access terms are set with the vendor before access begins.
You buy under a negotiated contract, not by hours or metered usage. There is no per-query or pay-as-you-go meter. You agree on scope and price with the vendor, then access the dataset under those terms. Your cost does not change based on how often you analyze the data.
The dataset draws on de-identified, longitudinal real-world data covering Rheumatoid Arthritis patients. It links electronic medical records, claims, labs, patient-reported outcomes, and social determinants. It includes AI-estimated clinical measures such as the eCDAI. Confirm the specific variables and follow-up window with the vendor during contracting.
www.om1.com+1
Helpful?
Vendor refund policy
No refunds offered. For any questions, please e-mail us at info@om1.com .
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA) .
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Additional details
You will receive access to the following data sets.
Data set name | Type | Historical revisions | Future revisions | Sensitive information | Data dictionaries | Data samples |
|---|---|---|---|---|---|---|
Adalimumab drug switching in Rheumatoid Arthritis | All historical revisions | All future revisions | Not included | Not included |
Similar products
Machine Learning model to predict the Adverse Drug Reactions.
Engage in our BioLLM Acceleration program and transform the traditionally costly and protracted drug discovery process. Within 10-12 weeks, our experts build model architectures using BioLLMs such as Protein and DNA language models customized to your proprietary and expanded public datasets. By leveraging generative AI, we are able to exceed the limits of physical screening for bigger sampling and better candidate selection. Our work concludes with a comprehensive Proof of Concept (POC), model performance comparison, resulting model, intermediate datasets and more – paving the way for broader training initiatives and productization.
Enhance drug discovery with Loka’s Agentic Drug Discovery program, employing advanced AI technologies and intuitive chat interfaces for streamlined research workflows.
Accelerate your drug discovery process with Loka's Drug Targets Identification, Clinical Proof & Patent Screening program, integrating AI-driven analytics and multi-modal data to identify and prioritize drug targets effectively.
ProteinMPNN (Protein Message Passing Neural Network) is a cutting-edge, deep learning-based, graph neural network designed to predict amino acid sequences for given protein backbones.